Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in APUS held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Hemenway Trust Co LLC | 274K | $490K | 0.0% | 2.518% | 0.04% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 96K | $172K | — | 0.881% | 0.00% |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 40K | $72K | +14.8% | 0.368% | 0.00% |
| 4 | VANGUARD FIDUCIARY TRUST CO | 24K | $43K | — | 0.221% | 0.00% |
| 5 | TWO SIGMA SECURITIES, LLC | 11K | $19K | — | 0.097% | 0.00% |
| 6 | UBS Group AG | 4K | $7K | +619.4% | 0.038% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in APUS — a direct measure of their conviction.
Filings activity in APUS during Q1 2026, grouped by how each filer changed its position.
Institutions that opened a new APUS position in Q1 2026
Institutions that fully closed their APUS position in Q1 2026
4 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 6 | 14% | 5.55% | +1.07 pp | $1M | +24% |
| Q4 2025 | 7 | 22% | 4.48% | 3.31 pp | $1M | 42% |
| Q3 2025 | 9 | +50% | 7.79% | +7.44 pp | $1M | +2146% |
| Q2 2025 | 6 | — | 0.35% | — | $0M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying APUS stock.
Based on Q1 2026 13F filings, institutional ownership of Apimeds Pharmaceuticals US, Inc stands at 5.5%, held across 6 reporting institutions.
Hemenway Trust Co LLC is the largest reported institutional holder of APUS, with approximately 274,000 shares worth $0.00B as of Q1 2026.
Yes — 1 widely-followed marquee investor appear among the top 25 institutional holders of APUS, including TWO SIGMA SECURITIES, LLC.
Our composite Smart Money Score for APUS is 53 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
3 institutions opened new positions in APUS during Q1 2026, while 4 fully exited. 3 added to existing positions and 0 trimmed.
APUS institutional ownership rose by 1.07 percentage points quarter-over-quarter, with a net change of -1 holders.
The top 10 institutions account for 100.0% of all reported 13F value in APUS, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Apimeds Pharmaceuticals US, Inc (APUS) Institutional Ownership